Oncostatin M is expressed in atherosclerotic lesions: A role for Oncostatin M in the pathogenesis of atherosclerosis

Atherosclerosis

Volumn 216, Issue 2, 2011, Pages 292-298

  Albasanz Puig, Adaia ^a   Murray, Jacqueline ^a   Preusch, Michael ^a   Coan, Daniel ^a   Namekata, Mayumi ^a   Patel, Yatin ^b   Dong, Zhao Ming ^a   Rosenfeld, Michael E ^a   Wijelath, Errol S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

ApoE ; Atherosclerosis; Carotid plaques; Oncostatin M; Smooth muscle cell; STAT 1; STAT 3

Indexed keywords

APOLIPOPROTEIN E; FIBRONECTIN; MESSENGER RNA; ONCOSTATIN M; STAT1 PROTEIN; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTIMA; MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SMOOTH MUSCLE FIBER;

ANIMALS; ATHEROSCLEROSIS; CELL MOVEMENT; CELL PROLIFERATION; EXTRACELLULAR MATRIX; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICE; MICE, TRANSGENIC; MYOCYTES, SMOOTH MUSCLE; ONCOSTATIN M; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES;

EID: 79957986058     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.02.003     Document Type: Article

References (40)

1. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138.
2. Raines E.W., Ferri N. Thematic review series: the immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res 2005, 46:1081-1092.
3. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004, 84:767-801.
4. Manea A., Tanase L.I., Raicu M., Simionescu M. JAK/STAT signaling pathway regulates nox1 and nox4-based NADPH oxidase in human aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2010, 30:105-112.
5. Ortiz-Munoz G., Martin-Ventura J.L., Hernandez-Vargas P., et al. Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29:525-531.
6. Seki Y., Kai H., Shibata R., et al. Role of the JAK/STAT pathway in rat carotid artery remodeling after vascular injury. Circ Res 2000, 87:12-18.
7. Hou T., Tieu B.C., Ray S., et al. Roles of IL-6-gp130 signaling in vascular inflammation. Curr Cardiol Rev 2008, 4:179-192.
8. Bazan J.F. Neuropoietic cytokines in the hematopoietic fold. Neuron 1991, 7:197-208.
9. Nishibe T., Parry G., Ishida A., et al. Oncostatin M promotes biphasic tissue factor expression in smooth muscle cells: evidence for Erk-1/2 activation. Blood 2001, 97:692-699.
10. Kastl S.P., Speidl W.S., Katsaros K.M., et al. Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. Blood 2009, 114:2812-2818.
11. Strand K., Murray J., Aziz S., et al. Induction of the urokinase plasminogen activator system by oncostatin M promotes endothelial migration. J Cell Biochem 2000, 79:239-248.
12. Nagata T., Kai H., Shibata R., et al. Oncostatin M an interleukin-6 family cytokine, upregulates matrix metalloproteinase-9 through the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cultured smooth muscle cells. Arterioscler Thromb Vasc Biol 2003, 23:588-593.
13. Shioi A., Katagi M., Okuno Y., et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ Res 2002, 91:9-16.
14. Langdon C., Leith J., Smith F., Richards C.D. Oncostatin M stimulates monocyte chemoattractant protein-1- and interleukin-1-induced matrix metalloproteinase-1 production by human synovial fibroblasts in vitro. Arthritis Rheum 1997, 40:2139-2146.
15. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
16. Brenmoehl J., Lang M., Hausmann M., et al. Evidence for a differential expression of fibronectin splice forms ED-A and ED-B in Crohn's disease (CD) mucosa. Int J Colorectal Dis 2007, 22:611-623.
17. Ishida A., Murray J., Saito Y., et al. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol 2001, 188:359-368.
18. Orr A.W., Hastings N.E., Blackman B.R., Wamhoff B.R. Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J Vasc Res 2010, 47:168-180.
19. Jeziorska M., Woolley D.E. Local neovascularization and cellular composition within vulnerable regions of atherosclerotic plaques of human carotid arteries. J Pathol 1999, 188:189-196.
20. McCarthy M.J., Loftus I.M., Thompson M.M., et al. Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J Vasc Surg 1999, 30:261-268.
21. Dunmore B.J., McCarthy M.J., Naylor A.R., Brindle N.P. Carotid plaque instability and ischemic symptoms are linked to immaturity of microvessels within plaques. J Vasc Surg 2007, 45:155-159.
22. Modur V., Feldhaus M.J., Weyrich A.S., et al. Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest 1997, 100:158-168.
23. de Kleijn D.P., Moll F.L., Hellings W.E., et al. Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events. Arterioscler Thromb Vasc Biol 2010, 30:612-619.
24. Hellings W.E., Peeters W., Moll F.L., et al. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study. Circulation 2010, 121:1941-1950.
25. Demyanets S., Kaun C., Rychli K., et al. Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon-gamma. Basic Res Cardiol 2010, Epub ahead of print.
26. Rychli K., Kaun C., Hohensinner P.J., et al. The inflammatory mediator oncostatin M induces angiopoietin 2 expression in endothelial cells in vitro and in vivo. J Thromb Haemost 2010, 8:596-604.
27. Vasse M., Pourtau J., Trochon V., et al. Oncostatin M induces angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999, 19:1835-1842.
28. Wijelath E.S., Carlsen B., Cole T., et al. Oncostatin M induces basic fibroblast growth factor expression in endothelial cells and promotes endothelial cell proliferation, migration and spindle morphology. J Cell Sci 1997, 110(Pt 7):871-879.
29. Demyanets S., Kaun C., Rychli K., et al. The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways. Am J Physiol Heart Circ Physiol 2007, 293:H1962-H1968.
30. Bernard C., Merval R., Lebret M., et al. Oncostatin M induces interleukin-6 and cyclooxygenase-2 expression in human vascular smooth muscle cells: synergy with interleukin-1{beta}. Circ Res 1999, 85:1124-1131.
31. Faffe D.S., Flynt L., Mellema M., et al. Oncostatin M causes VEGF release from human airway smooth muscle: synergy with IL-1beta. Am J Physiol Lung Cell Mol Physiol 2005, 288:L1040-L1048.
32. White E.S., Baralle F.E., Muro A.F. New insights into form and function of fibronectin splice variants. J Pathol 2008, 216:1-14.
33. Dubin D., Peters J.H., Brown L.F., et al. Balloon catheterization induced arterial expression of embryonic fibronectins. Arterioscler Thromb Vasc Biol 1995, 15:1958-1967.
34. Glukhova M.A., Frid M.G., Shekhonin B.V., et al. Expression of extra domain A fibronectin sequence in vascular smooth muscle cells is phenotype dependent. J Cell Biol 1989, 109:357-366.
35. Castellani P., Viale G., Dorcaratto A., et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994, 59:612-618.
36. Seidel H.M., Lamb P., Rosen J. Pharmaceutical intervention in the JAK/STAT signaling pathway. Oncogene 2000, 19:2645-2656.
37. Regis G., Pensa S., Boselli D., et al. Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol 2008, 19:351-359.
38. Chin Y.E., Kitagawa M., Su W.C., et al. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996, 272:719-722.
39. Sano S., Itami S., Takeda K., et al. Keratinocyte-specific ablation of STAT3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 1999, 18:4657-4668.
40. Zhang F., Li C., Halfter H., Liu J. Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene 2003, 22:894-905.